Evaluating Cognition in Individuals with Huntington Disease: NeuroQoL Cognitive Functioning Measures
Document Type
Article
Version Deposited
Accepted for publication (PostPrint)
Publication Date
3-1-2018
Publication Title
Quality of Life Research
DOI
10.1007/s11136-017-1755-6
Abstract
PURPOSE: Cognitive functioning impacts health-related quality of life (HRQOL) for individuals with Huntington disease (HD). The Neuro-QoL includes two patient-reported outcome (PRO) measures of cognition-Executive Function (EF) and General Concerns (GC). These measures have not previously been validated for use in HD. The purpose of this analysis is to evaluate the reliability and validity of the Neuro-QoL Cognitive Function measures for use in HD.
METHODS: Five hundred ten individuals with prodromal or manifest HD completed the Neuro-QoL Cognition measures, two other PRO measures of HRQOL (WHODAS 2.0 and EQ5D), and a depression measure (PROMIS Depression). Measures of functioning The Total Functional Capacity and behavior (Problem Behaviors Assessment) were completed by clinician interview. Objective measures of cognition were obtained using clinician-administered Symbol Digit Modalities Test and the Stroop Test (Word, Color, and Interference). Self-rated, clinician-rated, and objective composite scores were developed. We examined the Neuro-QoL measures for reliability, convergent validity, discriminant validity, and known-groups validity.
RESULTS: Excellent reliabilities (Cronbach's alphas ≥ 0.94) were found. Convergent validity was supported, with strong relationships between self-reported measures of cognition. Discriminant validity was supported by less robust correlations between self-reported cognition and other constructs. Prodromal participants reported fewer cognitive problems than manifest groups, and early-stage HD participants reported fewer problems than late-stage HD participants.
CONCLUSIONS: The Neuro-QoL Cognition measures provide reliable and valid assessments of self-reported cognitive functioning for individuals with HD. Findings support the utility of these measures for assessing self-reported cognition.
Recommended Citation
Lai JS, Goodnight S, Downing NR, Ready RE, Paulsen JS, Kratz AL, Stout JC, McCormack MK, Cella D, Ross C, Russell J, Carlozzi NE.Evaluating cognition in individuals with Huntington disease: NeuroQoL cognitive functioning measures. Quality of Life Research. 2018 Mar;27(3):811-822. Epub 2017 Dec 8. doi: 10.1007/s11136-017-1755-6. PMID: 29222609. PMCID: PMC5845825.
Included in
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Investigative Techniques Commons, Neurology Commons, Pathological Conditions, Signs and Symptoms Commons, Public Health Commons
Comments
This is a post-peer-review, pre-copyedit version of an article published in Quality of Life Research. The final authenticated version is available online at: http://dx.doi.org/10.1007/s11136-017-1755-6.